GOTHENBERG, Sweden – Bruker today announced that it is collaborating with AstraZeneca to bring new state-of-the-art technology to a major Swedish national research center for drug development.  Building on the AstraZeneca strategy of innovation through global partnerships, a collaboration between the Swedish NMR Center at the University of Gothenburg and AstraZeneca now offers advanced dynamic nuclear polarization (DNP) – nuclear magnetic resonance (NMR) technology and workflows from Bruker with the goal to significantly decrease drug development times.